Compare ARVN & URG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | URG |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 608.7M |
| IPO Year | 2018 | 2006 |
| Metric | ARVN | URG |
|---|---|---|
| Price | $7.85 | $1.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | ★ $15.05 | $2.57 |
| AVG Volume (30 Days) | 705.4K | ★ 5.2M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | $27,207,000.00 |
| Revenue This Year | N/A | $200.42 |
| Revenue Next Year | N/A | $98.46 |
| P/E Ratio | $4.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.97 | $1.12 |
| 52 Week High | $14.22 | $2.35 |
| Indicator | ARVN | URG |
|---|---|---|
| Relative Strength Index (RSI) | 33.46 | 32.01 |
| Support Level | N/A | N/A |
| Resistance Level | $9.69 | $1.46 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 0.58 | 0.00 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project; Shirley Basin; Other U.S. Projects.